Chengdu Yuanpu Biotechnology

Chengdu Yuanpu Biotechnology is a biopharmaceutical company specializing in the discovery and development of innovative small molecule drugs, with a core focus on protein degradation technologies. The company utilizes its expertise in PROTACs (Proteolysis-targeting chimeras) and molecular glues to target disease-causing proteins that have traditionally been considered undruggable. Based in Chengdu, China, Yuanpu is advancing a pipeline primarily focused on oncology and other high-need therapeutic areas. The firm is backed by prominent venture capital investors, including GL Ventures and Sequoia China, and aims to translate cutting-edge science into transformative clinical therapies. By integrating advanced medicinal chemistry with biological screening, Yuanpu seeks to accelerate the delivery of next-generation treatments to patients.